Skip to main content
Equibles

AARTIDRUGS · Aarti Drugs Limited · Documents

Use AARTIDRUGS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AARTIDRUGS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
507.35 INR -1.40 (-0.28%) At close · Nov 13
Rebalance outlook locked
Market Cap
46.31B INR
Shares
91.27M
Volume · Nov 13 1.56M Avg daily vol (3M) 872.68K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Nov 4, 2026
2026
Nov 4
Earnings call
Revenue hits record Rs. 829 crores as EBITDA rises 63%

Aarti Drugs reported Q2 FY27 revenue of Rs. 829 crores, up 27%, as EBITDA rose 63% to Rs. 138 crores and PAT increased 83% to Rs. 83 crores.

4 source passages
I am pleased to report that Q2 FY27 has been a milestone quarter for Aarti Drugs Limited. For the first time ever, our total consolidated revenue was at Rs. 829 crores in a single quarter, 27% higher than a year ago. EBITDA grew 63% to Rs. 138 crores, the highest quarterly EBITDA we have ever reported, with our EBITDA margin for the quarter reaching 16.6%, up 370 basis points year-on-year basis and the highest we have achieved in nearly 6 years. Profit after tax rose 83% to Rs. 83 crores. Open the document at this passage
Showing 1–3 of 3 documents